001     169822
005     20240229133656.0
024 7 _ |a 10.15252/emmm.202113953
|2 doi
024 7 _ |a pmid:34254741
|2 pmid
024 7 _ |a 1715-4684
|2 ISSN
024 7 _ |a 1757-4676
|2 ISSN
024 7 _ |a 1757-4684
|2 ISSN
024 7 _ |a altmetric:109298911
|2 altmetric
037 _ _ |a DKFZ-2021-01569
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Friedrich, Mirco
|0 P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c
|b 0
|e First author
|u dkfz
245 _ _ |a Intrathecal activation of CD8+ memory T cells in IgG4-related disease of the brain parenchyma.
260 _ _ |a Heidelberg
|c 2021
|b EMBO Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1698997531_23207
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D170#LA:D170# / 2021 Aug 9;13(8):e13953 / HI-TRON
520 _ _ |a IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder signified by aberrant infiltration of IgG4-restricted plasma cells into a variety of organs. Clinical presentation is heterogeneous, and pathophysiological mechanisms of IgG4-RD remain elusive. There are very few cases of IgG4-RD with isolated central nervous system manifestation. By leveraging single-cell sequencing of the cerebrospinal fluid (CSF) of a patient with an inflammatory intracranial pseudotumor, we provide novel insights into the immunopathophysiology of IgG4-RD. Our data illustrate an IgG4-RD-associated polyclonal T-cell response in the CSF and an oligoclonal T-cell response in the parenchymal lesions, the latter being the result of a multifaceted cell-cell interaction between immune cell subsets and pathogenic B cells. We demonstrate that CD8+ T effector memory cells might drive and sustain autoimmunity via macrophage migration inhibitory factor (MIF)-CD74 signaling to immature B cells and CC-chemokine ligand 5 (CCL5)-mediated recruitment of cytotoxic CD4+ T cells. These findings highlight the central role of T cells in sustaining IgG4-RD and open novel avenues for targeted therapies.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a CSF single-cell sequencing
|2 Other
650 _ 7 |a IgG4-related disease
|2 Other
650 _ 7 |a cytotoxic T helper cell
|2 Other
650 _ 7 |a inflammatory pseudotumor
|2 Other
650 _ 7 |a pathogenic B-cell
|2 Other
700 1 _ |a Kehl, Niklas
|0 P:(DE-He78)fad274ed48f42202270f60e22b0bcdd1
|b 1
|u dkfz
700 1 _ |a Engelke, Niko
|b 2
700 1 _ |a Kraus, Josephine
|b 3
700 1 _ |a Lindner, Katharina
|0 P:(DE-He78)9c599f876c762bc78d289674c15ba4a5
|b 4
|u dkfz
700 1 _ |a Münch, Philipp
|0 P:(DE-He78)66bc424b1c5322674c5f9c9d7131f760
|b 5
|u dkfz
700 1 _ |a Mildenberger, Iris
|0 P:(DE-He78)7daa75b87e6d6e291016ecb54f60b6b3
|b 6
|u dkfz
700 1 _ |a Groden, Christoph
|b 7
700 1 _ |a Gass, Achim
|b 8
700 1 _ |a Etminan, Nima
|b 9
700 1 _ |a Fatar, Marc
|b 10
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 11
|u dkfz
700 1 _ |a Reuss, David
|0 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa
|b 12
|u dkfz
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 13
|u dkfz
700 1 _ |a Bunse, Lukas
|0 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985
|b 14
|e Last author
|u dkfz
773 _ _ |a 10.15252/emmm.202113953
|0 PERI:(DE-600)2485479-7
|n 8
|p e13953
|t EMBO molecular medicine
|v 13
|y 2021
|x 1757-4684
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169822
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)fad274ed48f42202270f60e22b0bcdd1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)9c599f876c762bc78d289674c15ba4a5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)66bc424b1c5322674c5f9c9d7131f760
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)7daa75b87e6d6e291016ecb54f60b6b3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Tumor immunology
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO MOL MED : 2019
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-04
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2021-02-04
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-04
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EMBO MOL MED : 2019
|d 2021-02-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-04
920 1 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D170-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21